Antibodies to opgl

Abstract

Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.

1 . (canceled) 
     
     
         2 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises a human IgG2 heavy chain comprising the amino acid sequence of SEQ ID NO: 13, and wherein the light chain comprises a human kappa light chain comprising the amino acid sequence of SEQ ID NO: 14, and wherein the antibody interacts with an osteoprotegerin ligand (OPGL) and inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR). 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . The antibody of  claim 2 , which is fully human. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . A pharmaceutical composition comprising an antibody of  claim 2 . 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . An antibody, comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of SEQ ID NO: 2 from residue 20 to residue 467, and the light chain comprises an amino acid sequence of SEQ ID NO: 4 from residue 21 to residue 235, wherein the antibody interacts with an osteoprotegerin ligand (OPGL) and inhibits binding of OPGL to an osteoclast differentiation and activation receptor (ODAR). 
     
     
         16 . A pharmaceutical composition comprising an antibody of  claim 8 . 
     
     
         17 . A pharmaceutical composition comprising an antibody of  claim 15 .